Antithymocyte globulin with or without cyclosporin A: 11-Year follow-up of a randomized trial comparing treatments of aplastic anemia

Blood

Volumn 101, Issue 4, 2003, Pages 1236-1242

  Frickhofen, Norbert ^a   Heimpel, Hermann ^b   Kaltwasser, Joachim P ^b   Schrezenmeier, Hubert ^b  

^a DR HORST SCHMIDT KLINIKEN   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; LYMPHOCYTE ANTIBODY; METHYLPREDNISOLONE; THYMOCYTE ANTIBODY;

APLASTIC ANEMIA; ARTICLE; BONE NECROSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; EDEMA; FOLLOW UP; GERMANY; GINGIVA HYPERPLASIA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPERTENSION; HYPERTRICHOSIS; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MUSCLE CRAMP; MYELODYSPLASTIC SYNDROME; OSTEOPOROSIS; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REMISSION; SALVAGE THERAPY; SOLID TUMOR; SURVIVAL RATE;

EID: 0037441586     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-04-1134     Document Type: Article

References (31)

1. Young NS. Acquired aplastic anemia. Ann Intern Med. 2002;136:534-546.
2. Deeg HJ, Leisenring W, Storb R, et al. Long-term outcome after marrow transplantation for severe aplastic anemia. Blood. 1998;91:3637-3645.
3. Deeg HJ, Seidel K, Casper J, et al. Marrow transplantation from unrelated donors for patients with severe aplastic anemia who have failed immunosuppressive therapy. Biol Blood Marrow Transplant. 1999;5:243-252.
4. Champlin R, Ho W, Bayever E, et al. Treatment of aplastic anemia: results with bone marrow transplantation, antithymocyte globulin, and a monoclonal anti-T cell antibody. Prog Clin Biol Res. 1984;148:227-238.
5. Camitta B, O'Reilly RJ, Sensenbrenner L, et al. Antithoracic duct lymphocyte globulin therapy of severe aplastic anemia. Blood. 1983;62:883-888.
6. Bacigalupo A, Brand R, Obeto R, et al. Treatment of acquired aplastic anemia: bone marrow transplantation compared with immunsuppressive therapy - the European Group for Blood and Marrow Transplantation experience. Semin Hematol. 2000;37:69-80.
7. Frickhofen N, Kaltwasser JP, Schrezenmeier H, et al. Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine: the German Aplastic Anemia Study Group. N Engl J Med. 1991;324:1297-1304.
8. Najean Y, Haguenauer O. Long-term (5 to 20 years) evolution of nongrafted aplastic anemia. Blood. 1990;76:2222-2228.
9. Doney K, Leisenring W, Storb R, Appelbaum FR. Primary treatment of acquired aplastic anemia: outcomes with bone marrow transplantation and immunosuppressive therapy: Seattle Bone Marrow Transplant Team. Ann Intern Med. 1997;126:107-115.
10. Bacigalupo A, Chaple M, Hows J, et al. Treatment of aplastic anaemia (AA) with antilymphocyte globulin (ALG) and methylprednisolone (MPred) with or without androgens: a randomized trial from the EBMT SAA working party. Br J Haematol. 1993;83:145-151.
11. Gluckman E, Esperou-Bourdeau H, Baruchel A, et al. Multicenter randomized study comparing cyclosporine-A alone and antithymocyte globulin with prednisone for treatment of severe aplastic anemia. Blood. 1992;79:2540-2546.
12. Marsh J, Schrezenmeier H, Marin P, et al. Prospective randomized multicenter study comparing cyclosporin alone versus the combination of anti-thymocyte globulin and cyclosporin for treatment of patients with nonsevere aplastic anemia: a report from the European Blood and Marrow Transplant (EBMT) Severe Aplastic Anaemia Working Party. Blood. 1999;93:2191-2195.
13. Kojima S, Hibi S, Kosaka Y, et al. Immunosuppressive therapy using antithymocyte globulin, cyclosporine, and danazol with or without human granulocyte colony-stimulating factor in children with acquired aplastic anemia. Blood. 2000;96:2049-2054.
14. Schrezenmeier H. Treatment of aplastic anaemia with immunosuppression and hematopoietic growth factors: 25th Annual EBMT Meeting Educational Book. Hamburg, Germany: 1999;123-131.
15. Lee GR, Foerster J, Lukens JN, Paraskevas F, Rodgers GM. Wintrobe's Clinical Hematology. 10th ed. Baltimore, MD: Lippincott Williams & Wilkins; 1998.
16. Dixon DO, McLaughlin P, Hagemeister FB, et al. Reporting outcomes in Hodgkin's disease and lymphoma. J Clin Oncol. 1987;5:1670-1672.
17. Rosenfeld SJ, Kimball J, Vining D, Young NS. Intensive immunosuppression with antithymocyte globulin and cyclosporine as treatment for severe acquired aplastic anemia. Blood. 1995;85:3058-3065.
18. Bacigalupo A, Bruno B, Saracco P, et al. Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients. European Group for Blood and Marrow Transplantation (EBMT) Working Party on Severe Aplastic Anemia and the Gruppo Italiano Trapianti di Midolio Osseo (GITMO). Blood. 2000;95:1931-1934.
19. Raghavachar A, Kolbe K, Höffken K, et al. Standard immunosuppression is superior to cyclosporine/filgrastim in severe aplastic anemia: the German multicenter study [abstract]. Bone Marrow Transplant. 1999;23(suppl 1):S31.
20. Führer M, Burdach S, Ebell W, etal. Relapse and clonal disease in children with aplastic anemia (AA) after immunosuppressive therapy (IST): the SAA 94 experience. German/Austrian Pediatric Aplastic Anemia Working Group. Klin Pädiatr. 1998;210:173-179.
21. Schrezenmeler H, Hinterberger W, Hows J, et al. Second immunosuppressive treatment of patients with aplastic anaemia not responding to the first course of immunosuppression (IS): a report from the Working Party on Severe Aplastic Anaemia of the EBMT [abstract]. Bone Marrow Transplant. 1995;15(suppl 2):10.
22. Storb R, Blume KG, O'Donnell MR, et al. Cyclophosphamide and antithymocyte globulin to condition patients with aplastic anemia for allogeneic marrow transplantations: the experience in four centers. Biol Blood Marrow Transplant. 2001;7:39-44.
23. Weinberger M, Elater I, Marshall D, et al. Patterns of infection in patients with aplastic anemia and the emergence of aspergillus as a major cause of death. Medicine. 1992;71:24-43.
24. Schrezenmeier H, Marin P, Raghavachar A, et al. Relapse of aplastic anaemia after immunosuppressive treatment: a report from the European Bone Marrow Transplantation Group SAA Working Party. Br J Haematol. 1993;85:371-377.
25. Socie G, Rosenfeld S, Frickhofen N, Gluckman E, Tichelli A. Late clonal diseases of treated aplastic anemia. Semin Hematol. 2000;37:91-101.
26. Ohara A, Kojima S, Hamajima N, et al. Myelodysplastic syndrome and acute myelogenous leukemia as a late clonal complication in children with acquired aplastic anemia. Blood. 1997;90:1009-1013.
27. Kojima S, Horibe K, Inaba J, et al. Long-term outcome of acquired aplastic anaemia in children: comparison between immunosuppressive therapy and bone marrow transplantation. Br J Haematol. 2000;111:321-328.
28. Locasciulli A, Arcese W, Locatelli F, Di Bona E, Bacigalupo A. Treatment of aplastic anaemia with granulocyte-colony stimulating factor and risk of malignancy: Italian Aplastic Anaemia Study Group. Lancet. 2001;357:43-44.
29. Dantal J, Hourmant M, Cantarovich D, et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet. 1998;351:623-628.
30. Jensen P, Hansen S, Moller B, et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol. 1999;40:177-186.
31. Schrezenmeier H, Passweg J, Oneto R, et al. Aplastic Anemia Registry: Report 2002 [abstract]. Bone Marrow Transplant. 2002;29(suppl 2):S54.